<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04746729</url>
  </required_header>
  <id_info>
    <org_study_id>C20-01</org_study_id>
    <secondary_id>2020-A01037-32/1</secondary_id>
    <nct_id>NCT04746729</nct_id>
  </id_info>
  <brief_title>Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy</brief_title>
  <acronym>HARMONIC-RT</acronym>
  <official_title>Health Effects of CArdiac FluoRoscopy and MOderN RadIotherapy in PediatriCs - Radiotherapy (HARMONIC-RT)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut National de la Santé Et de la Recherche Médicale, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Barcelona Institute for Global Health</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The West German Proton Therapy Centre, Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Francois Baclesse</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>KU Leuven</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Princess Maxima Center for Pediatric Oncology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Medical Center Groningen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stockholm University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Research Council, Institute of Clinical Physiology, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Zurich</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Commissariat A L'energie Atomique</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Luxembourg Institute of Science and Technology</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Essen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aarhus University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut National de la Santé Et de la Recherche Médicale, France</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of the HARMONIC-RT study is to evaluate late health and social outcomes of modern&#xD;
      external beam radiotherapy techniques in paediatric patients, based on the setting-up of a&#xD;
      European, long-term registry complemented by a biobank.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Specific objectives:&#xD;
&#xD;
        -  To develop the infrastructure and instruments for setting-up a European, long-term&#xD;
           registry of paediatric patients treated with modern external radiotherapy techniques ;&#xD;
&#xD;
        -  To assess the incidence and severity of late health outcomes, primarily endocrine&#xD;
           dysfunctions, cardiovascular toxicities, neurovascular damages, and subsequent primary&#xD;
           neoplasms, in relation to the dose-volume distribution to non-targeted organs and&#xD;
           tissues, radiation delivery technique and beam quality factors, and potential modifying&#xD;
           factors (i.e. age at exposure, genetic predispositions, comorbidities, and systemic&#xD;
           treatments including chemotherapy, targeted therapy, immunotherapy and hormonal drugs)&#xD;
           that may underlie differences in individual susceptibility for these outcomes ;&#xD;
&#xD;
        -  To assess societal aspects of advances in radiotherapy, primarily health-related quality&#xD;
           of life and academic achievement, in paediatric patients treated with modern external&#xD;
           radiotherapy techniques.&#xD;
&#xD;
      Secondary scientific objectives:&#xD;
&#xD;
        -  To assess multidimensional fatigue in paediatric patients treated with modern external&#xD;
           radiotherapy techniques, and identify clinical and therapeutic determinants of fatigue;&#xD;
&#xD;
        -  To improve estimation of patient-specific doses to the whole body and non-targeted&#xD;
           organs and substructures from different radiotherapy delivery techniques;&#xD;
&#xD;
        -  To investigate radiation-induced cellular responses and biological mechanisms related to&#xD;
           the occurrence of vascular diseases and subsequent primary neoplasms in samples of blood&#xD;
           and saliva ; to identify biomarkers of susceptibility and health effects ; to evaluate&#xD;
           differences in disease biomarkers in relation to the radiation delivery technique and&#xD;
           beam quality factors ; to explore the relevance of the use of saliva as a biosampling&#xD;
           method for paediatric cohorts regarding feasibility and the quality and reproducibility&#xD;
           for different measured biomarkers.&#xD;
&#xD;
      Secondary strategic objectives:&#xD;
&#xD;
        -  To promote sustained collaborative research activities for improvement of patient care,&#xD;
           and inform health care providers and policy makers on the clinical and social impact of&#xD;
           advances in radiotherapy in paediatric settings;&#xD;
&#xD;
        -  To serve as a pilot for a future long-term pan-European registry of children and&#xD;
           adolescents treated with particle and photon beam therapy, including a biobank of saliva&#xD;
           and blood samples collected before and after treatment;&#xD;
&#xD;
        -  To contribute in future collaborative projects with existing cohorts or registries in&#xD;
           Europe&#xD;
&#xD;
        -  To contribute in future international research studies on late outcomes of modern&#xD;
           radiotherapy techniques for management of paediatric cancers&#xD;
&#xD;
      Funding: The HARMONIC project has received funding from the Euratom research and training&#xD;
      programme 2014-2018 under grant agreement No 847707.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2022</start_date>
  <completion_date type="Anticipated">September 30, 2040</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2040</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>20 Years</target_duration>
  <primary_outcome>
    <measure>Endocrinopathies</measure>
    <time_frame>up to 20 years after RT</time_frame>
    <description>Late health outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cardiovascular diseases</measure>
    <time_frame>up to 20 years after RT</time_frame>
    <description>Late health outcomes&#xD;
Neurovascular diseases&#xD;
Second and subsequent primary neaoplasms</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Neurovascular diseases</measure>
    <time_frame>up to 20 years after RT</time_frame>
    <description>Late health outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Second and subsequent primary neaoplasms</measure>
    <time_frame>up to 20 years after RT</time_frame>
    <description>Late health outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Health-related quality of life (physical, emotional, social, and school functioning) assessed by the PedsQL™ core scale (validated questionnaire)</measure>
    <time_frame>up to 10 years after radiation therapy or attained age 25 years, whichever occurs first</time_frame>
    <description>Late social outcomes</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Academic achievement</measure>
    <time_frame>up to 10 years after radiation therapy or attained age 25 years, whichever occurs first</time_frame>
    <description>Late social outcomes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dysfunctions in endocrine hormone levels</measure>
    <time_frame>up to 10 years after radiation therapy</time_frame>
    <description>measured as:&#xD;
insulin-like growth factor-1,&#xD;
anterior pituitary hormones (GH, ACTH, TSH, LH, FSH),&#xD;
thyroid hormones (fT3, fT4),&#xD;
sexual hormones</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood markers of cardiovascular diseases</measure>
    <time_frame>up to 10 years after radiation therapy</time_frame>
    <description>measured as blood markers (incl. troponin, BNP, CPK)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in imaging markers of cardiovascular diseases</measure>
    <time_frame>up to 10 years after radiation therapy</time_frame>
    <description>measured as cardiac echography parameters (incl. ejection fraction, diastolic function)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in imaging markers of neurovascular damages</measure>
    <time_frame>up to 5 years after radiation therapy</time_frame>
    <description>measured as scoring of large and small vessel damages</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood/saliva markers of protein activation relating to vascular damages</measure>
    <time_frame>up to 1 year after radiation therapy</time_frame>
    <description>measured as signal quality of protein activity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood/saliva markers of oxidative stress response</measure>
    <time_frame>up to 1 year after radiation therapy</time_frame>
    <description>measured as markers of oxidative stress (incl. 8-oxo-dG, SOD2, DNA repair enzymes)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood/saliva markers of inflammatory response</measure>
    <time_frame>up to 1 year after radiation therapy</time_frame>
    <description>Inflammatory markers (incl. PTX3, CRP, NF-kB, IL-1 and IL10)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in blood/saliva markers of carcinogenesis</measure>
    <time_frame>up to 1 year after radiation therapy</time_frame>
    <description>Markers of carcinogenesis (incl. leukocyte telomere length, mitochondrial DNA copy number, circulating microRNA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Multidimensional fatigue (general, sleep/rest, and cognitive fatigue)</measure>
    <time_frame>up to 10 years after radiation therapy or attained age 25 years, whichever occurs first</time_frame>
    <description>PedsQL™ multidimensional fatigue scale (validated questionnaire)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical events other than those mentioned as primary outcomes</measure>
    <time_frame>up to 20 years after radiation therapy</time_frame>
    <description>Late morbidity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All-cause and cause-specific mortality</measure>
    <time_frame>up to 20 years after radiation therapy</time_frame>
    <description>Late mortality</description>
  </secondary_outcome>
  <enrollment type="Anticipated">2670</enrollment>
  <condition>Neoplasms</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <description>No intervention</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood plasma; blood serum; lymphocytes; saliva&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Children, adolescents and young adults treated with external beam radiation therapy for a&#xD;
        first primary neoplasm&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Retrospective inclusion of study participants&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  First external beam radiation therapy (EBRT) started in 2000 or after for management&#xD;
             of a first primary neoplasm&#xD;
&#xD;
          -  Age under 22 years at the time of first EBRT initiation&#xD;
&#xD;
          -  Radiation treatment plan (first EBRT) stored in DICOM format&#xD;
&#xD;
          -  Usual residency in the country of EBRT to enable a long-term follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with poor prognosis (e.g. diffuse pontine glioma or high grade glioma) at&#xD;
             first EBRT initiation&#xD;
&#xD;
          -  Prior external or internal radiation therapy&#xD;
&#xD;
          -  Patients who refused to participate in the study&#xD;
&#xD;
        Prospective inclusion of study participants&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Scheduled first EBRT for management of a first primary neoplasm&#xD;
&#xD;
          -  Age under 22 years at the time of scheduled first EBRT&#xD;
&#xD;
          -  Radiation treatment plan stored in DICOM format&#xD;
&#xD;
          -  Affiliate or beneficiary of health insurance (or any required equivalent as defined in&#xD;
             applicable national law)&#xD;
&#xD;
          -  Usual residency in the country of EBRT to enable a long-term follow-up&#xD;
&#xD;
          -  Signed informed consent/assent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with poor prognosis (e.g. diffuse pontine glioma or high grade glioma)&#xD;
&#xD;
          -  Prior external or internal radiation therapy;&#xD;
&#xD;
          -  Protected adults (persons under curatorship, tutorship / individuals under&#xD;
             guardianship by court order, persons deprived of their liberty)&#xD;
&#xD;
          -  Adult/parent(s)/legal representative(s) who cannot read or understand the informed&#xD;
             consent in the applicable language(s) in the country of EBRT&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Isabelle Thierry-chef, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Barcelona Institute for Global Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Beate Timmermann, MD, PhD</last_name>
    <phone>+49 201 723 6430</phone>
    <email>beate.timmermann@uk-essen.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Neige Journy, PhD</last_name>
    <phone>+33 142 11 54 27</phone>
    <email>neige.journy@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>KU Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sofie Isebaert</last_name>
      <email>sofie.isebaert@uzleuven.be</email>
    </contact>
    <investigator>
      <last_name>Karin Haustermans</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>An Michiels</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandra Jacobs</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Anne Uyttebroeck</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Karen Van Beek</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Melissa Christiaens</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Aarhus University hospital</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yasmin Lassen</last_name>
      <email>yasmin.lassen@auh.rm.dk</email>
    </contact>
    <investigator>
      <last_name>Yasmin Lassen</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sanja Karabegovic</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Louise Tram Henriksen</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Régional François Baclesse</name>
      <address>
        <city>Caen</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Camille Vidaud</last_name>
      <email>c.vidaud@baclesse.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Juliette Thariat</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dinu Stefan</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jérémie Gaudichon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nadia Haddy</last_name>
      <email>nadia.haddy@gustaveroussy.fr</email>
    </contact>
    <investigator>
      <last_name>Stéphanie Bolle</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Brice Fresneau</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nadia Haddy</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Hospital Essen, The West German Proton Therapy Centre Essen</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martina Wette</last_name>
      <email>martina.wette@uk-essen.de</email>
    </contact>
    <investigator>
      <last_name>Beate Timmermann</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Denmark</country>
    <country>France</country>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>https://harmonicproject.eu/</url>
    <description>Project's website</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 14, 2020</study_first_submitted>
  <study_first_submitted_qc>February 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 10, 2021</study_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>Oncology</keyword>
  <keyword>Paediatrics</keyword>
  <keyword>Late toxicities</keyword>
  <keyword>Radiation-induced neoplasms</keyword>
  <keyword>Radiation-induced vascular damages</keyword>
  <keyword>Radiation-induced cardiac damages</keyword>
  <keyword>Radiation-induced endocrine damages</keyword>
  <keyword>Quality of life</keyword>
  <keyword>Social outcomes</keyword>
  <keyword>External beam radiotherapy</keyword>
  <keyword>Photon therapy</keyword>
  <keyword>Proton therapy</keyword>
  <keyword>Cohort</keyword>
  <keyword>Registry</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

